Maximizing the potential of bevacizumab in cancer treatment Journal Article
| Authors: | Bergsland, E.; Dickler, M. N. |
| Article Title: | Maximizing the potential of bevacizumab in cancer treatment |
| Abstract: | Promising results have been obtained with bevacizumab (Avestin™; Genentech, Inc.; South San Francisco, CA) in clinical trials in patients with a range of solid tumors; however, to maximize the potential of this agent, further research is needed to clarify a number of important issues. These include the optimization of bevacizumab dosage and schedule of administration, the potential value of this agent in combination with other treatment modalities like chemotherapy and radiation, the management of toxicities, and the selection of patients most likely to benefit from treatment. Intriguing results from two recent phase III trials highlight the need for a better understanding of the best ways to incorporate bevacizumab into clinical practice. Ultimately, maximizing the potential value of this agent may require a more thorough understanding of bevacizumab's mechanism of action and the pathways mediating resistance. |
| Keywords: | cancer survival; vascular endothelial growth factor a; unclassified drug; thalidomide; clinical trial; bevacizumab; erlotinib; hypertension; multimodality cancer therapy; patient selection; solid tumor; conference paper; paclitaxel; cancer radiotherapy; chemotherapy; rituximab; clinical practice; neoplasms; colorectal cancer; carboplatin; breast cancer; bleeding; antineoplastic combined chemotherapy protocols; drug administration schedule; tumor markers, biological; dose-response relationship, drug; angiogenesis; cancer therapy; antibodies, monoclonal; drug mechanism; thromboembolism; maximum tolerated dose; trastuzumab; drug dose regimen; angiogenesis inhibitors; epistaxis; beta interferon; proteinuria; nephrotic syndrome; clinical trials; multidrug resistance; solid tumors; humans; human; priority journal; peginterferon beta2b |
| Journal Title: | The Oncologist |
| Volume: | 9 |
| Issue: | Suppl. 1 |
| ISSN: | 1083-7159 |
| Publisher: | Oxford University Press |
| Date Published: | 2004-06-01 |
| Start Page: | 36 |
| End Page: | 42 |
| Language: | English |
| DOI: | 10.1634/theoncologist.9-suppl_1-36 |
| PROVIDER: | scopus |
| PUBMED: | 15178814 |
| DOI/URL: | |
| Notes: | Oncologist -- Cited By (since 1996):55 -- Export Date: 16 June 2014 -- CODEN: OCOLF -- Source: Scopus |
